The use of cardiovascular system medicines in Norway has shown a steady increase from 2024 to 2028. The value in 2023 stood at _ (this initial value needs to be specified to complete the analysis accurately). From 2024 to 2028, the year-on-year growth rates were as follows:
- 2025: ~3.5% increase over 2024
- 2026: ~3.3% increase over 2025
- 2027: ~3.0% increase over 2026
- 2028: ~2.8% increase over 2027
Considering the compounded annual growth rate (CAGR) from 2024 to 2028, the average annual increase in use is approximately 3.2%.
Future trends to watch for include potential advancements in cardiovascular treatments, demographic changes such as an aging population, and the implementation of public health initiatives aimed at reducing cardiovascular risk factors. Additionally, innovation in digital health technologies could further impact the usage patterns of these medicines.
